V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330011818 | 330005432 | 1.61 | 59.8 | Palliative (P) | 2016-03-31 | 2016-04-04 | Ipilimumab | 2 | N | 330020412 | R-EPOCH |
| 330011819 | 330008965 | 1.7 | 75.9 | Palliative (P) | 2018-10-02 | 2019-01-23 | CYCLO + DOXORUBICIN + VINCRISTINE | N | N | 330020417 | BUSULFAN + MELPHALAN |
| 330011820 | 330005438 | null | 71.5 | Adjuvant (A) | 2014-08-13 | 2014-09-17 | CVD (skin) | N | N | 330020423 | CISPLATIN + GEMCITABINE |
| 330011821 | 330005440 | 0 | 68.35 | Adjuvant (A) | 2018-04-25 | 2018-04-25 | CHOP R - 21 days | 01 | N | 330020433 | PEI |
| 330011822 | 330005444 | 1.79 | 100.3 | Palliative (P) | 2018-10-25 | 2019-02-22 | Cyclophosphamide High Dose | 2 | null | 330020457 | VEIP |
| 330011823 | 330005445 | null | 107.15 | Adjuvant (A) | 2014-06-03 | 2014-06-03 | EMA | N | Y | 330020482 | EMA |
| 330011824 | 330005448 | 0.91 | null | Curative (C) | 2018-02-13 | 2018-08-26 | BEAM | 02 | N | 330020501 | BORTEZOMIB + RITUXIMAB |
| 330011825 | 330005452 | 1.5 | 18 | Curative (C) | 2015-11-26 | 2015-12-04 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | 330020527 | BORTEZOMIB |
| 330011826 | 330005454 | 1.58 | 57 | Neo-adjuvant (N) | null | 2013-11-01 | Clofarabine + Cytarabine | null | null | 330020552 | IFOSFAMIDE |
| 330011827 | 330005457 | 1.38 | 0 | Curative (C) | 2014-08-22 | 2014-12-09 | IPO | N | N | 330020565 | TRIPLE INTRATHECAL |
| 330011828 | 330005462 | 1.85 | 127 | Curative (C) | 2018-09-05 | 2018-10-01 | Cytarabine Low Dose | null | N | 330020590 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE |
| 330011829 | 330005464 | 1.08 | 87 | Adjuvant (A) | 2017-09-08 | 2017-10-03 | BLEOMYCIN + VINCRISTINE | N | N | 330020602 | ABIRATERONE |
| 330011830 | 330005468 | 1.82 | 71.6 | Palliative (P) | 2013-12-13 | 2013-12-13 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE | 02 | N | 330020635 | MIDOSTAURIN |
| 330011831 | 330005471 | 1.72 | 68.999 | Neo-adjuvant (N) | 2017-01-10 | 2017-04-05 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 330020665 | VIDE |
| 330011833 | 330005482 | 1.76 | 60 | Palliative (P) | 2017-10-07 | 2017-10-16 | IBRUTINIB | N | N | 330020710 | CARBOPLATIN + VINCRISTINE |
| 330011834 | 330005487 | 1.67 | 58.7 | Disease modification (D) | 2017-04-02 | 2017-05-14 | CISPLATIN + GEMCITABINE + RITUXIMAB | 2 | N | 330020733 | CYCLOPHOSPHAMIDE + DOXORUBICIN |
| 330011835 | 330008992 | null | 0 | Neo-adjuvant (N) | 2014-05-02 | 2014-06-21 | THALIDOMIDE | 02 | N | 330020744 | CLOFARABINE + CYCLO + CYTARABINE + ETOP |
| 330011836 | 330005497 | null | 58 | Curative (C) | 2014-03-21 | 2014-05-25 | CAPECITABINE + OXALIPLATIN | null | null | 330020832 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330011837 | 330005498 | 1.64 | 23.9 | Curative (C) | 2014-11-08 | 2014-12-27 | EMA | N | N | 330020835 | PAC-PLAT |
| 330011838 | 330009001 | 1.56 | null | Disease modification (D) | 2017-03-04 | 2017-07-02 | EMA/CO | N | N | 330020902 | CARBOPLATIN + VINCRISTINE |
| 330011839 | 330005509 | 0 | 82 | Curative (C) | 2018-02-23 | 2018-02-23 | VIDE | 2 | N | 330020955 | LIPOSOMAL DAUNORUBICIN |
| 330011840 | 330005509 | 1.73 | null | Neo-adjuvant (N) | 2015-03-26 | 2015-04-15 | CISPLATIN + FLUOROURACIL + RT | N | N | 330020955 | UKALL2014 |
| 330011841 | 330005511 | 1.77 | 29.25 | Not known (9) | 2016-01-05 | 2016-01-05 | GC Int Guide Excranial GermCell JEB | 02 | N | 330020977 | CISPLATIN + GEMCITABINE |
| 330011842 | 330011922 | 1.7 | 77 | Palliative (P) | null | 2018-04-14 | Cyclophosphamide High Dose | N | N | 330020984 | AML18 TRIAL |
| 330011843 | 330005515 | 1.6 | 86.7 | Adjuvant (A) | 2018-07-09 | 2018-10-25 | STS Rhabdomyosarcoma RMS 2005 IVA | null | N | 330020988 | CHOP R |
| 330011844 | 330005516 | null | null | Palliative (P) | 2014-06-15 | 2014-06-17 | Mitotane 5.5 - 10g | N | N | 330020998 | BORTEZOMIB |
| 330011845 | 330012521 | 1.61 | 109.2 | Disease modification (D) | 2014-12-19 | 2014-12-19 | Ifosfamide | Y | null | 330021007 | DHAP |
| 330011846 | 330005519 | 1.67 | 14.1 | Palliative (P) | 2014-03-26 | 2014-04-02 | DACTINOMYCIN | N | N | 330021026 | BEXAROTENE |
| 330011848 | 330005527 | null | 71.4 | Palliative (P) | 2014-08-22 | 2014-09-05 | Bortezomib +/- Dexamethasone | N | null | 330021093 | DACTINOMYCIN |
| 330011849 | 330005529 | 1.78 | 83.8 | Palliative (P) | null | 2014-11-18 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 330021096 | HYDROXYCARBAMIDE |
| 330011851 | 330009020 | 1.65 | 73.7 | Neo-adjuvant (N) | 2017-06-24 | 2017-06-24 | IMATINIB | N | null | 330021120 | IPILIMUMAB |
| 330011852 | 330009024 | 1.67 | 46.3 | Curative (C) | 2017-01-12 | 2017-01-19 | Imatinib 400mg | N | N | 330021153 | DOCETAXEL + NINTEDANIB |
| 330011853 | 330005546 | 1.48 | 18.1 | Palliative (P) | 2016-10-18 | 2017-02-06 | BLINATUMOMAB | N | N | 330021212 | CARBOPLATIN + CETUXIMAB + FU |
| 330011854 | 330005550 | null | null | null | 2016-10-28 | 2016-10-29 | CHOP - 14 days | 01 | N | 330021284 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 330011855 | 330009029 | 1.64 | 70 | Disease modification (D) | 2017-03-11 | 2017-08-24 | CAPECITABINE + OXALIPLATIN | N | N | 330021288 | EMA/CO |
| 330011856 | 330005555 | null | 96.5 | Palliative (P) | 2015-09-28 | 2015-09-29 | Doxorubicin + Methotrexate | 2 | N | 330021301 | BEAM |
| 330011857 | 330005556 | 1.73 | 92.2 | Curative (C) | 2014-03-08 | 2014-03-20 | CLOFARABINE | N | N | 330021309 | DOXORUBICIN + METHOTREXATE |
| 330011858 | 330005562 | 1.86 | 20.6 | Curative (C) | 2016-02-27 | 2016-04-05 | Cyclophosphamide TBI Allograft | 2 | N | 330021319 | CYCLOPHOSPHAMIDE + VINCRISTINE + LIPOSOMAL DOXORUBICIN |
| 330011859 | 330005565 | 1.73 | null | Curative (C) | 2016-06-17 | 2016-06-17 | Cytarabine Low Dose | 02 | N | 330021342 | LIPOSOMAL DAUNORUBICIN |
| 330011860 | 330005568 | 1.71 | null | Palliative (P) | 2017-08-08 | 2017-08-16 | Bortezomib + Cyclophos + Pred | 02 | N | 330021349 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330011861 | 330005572 | 1.78 | 60 | Curative (C) | 2016-12-28 | 2016-12-28 | IPO | N | N | 330021390 | FCR |
| 330011862 | 330005575 | 1.82 | null | Curative (C) | 2016-01-25 | 2016-02-04 | Cyclophosphamide + Vincristine | N | N | 330021428 | ECX |
| 330011863 | 330005580 | null | 75 | Neo-adjuvant (N) | 2015-07-20 | 2015-07-20 | Mitotane 2g | N | N | 330021489 | CAP |
| 330011864 | 330005582 | 1.63 | 123 | null | 2016-12-22 | 2016-12-23 | CISPLATIN + ETOPOSIDE + PACLITAXEL | null | null | 330021497 | BENDAMUSTINE |
| 330011865 | 330005586 | 0 | 110.6 | Curative (C) | 2014-09-29 | 2014-09-30 | Cyclophosphamide oral | N | N | 330021574 | CHLORAMBUCIL + RITUXIMAB |
| 330011866 | 330005591 | 1.91 | 75 | Curative (C) | null | 2014-02-01 | CHLORAMBUCIL + RITUXIMAB | null | N | 330021602 | CYTARABINE INTRATHECAL |
| 330011867 | 330005598 | 1.58 | 57.7 | Palliative (P) | 2016-08-30 | 2016-09-20 | EMA | N | N | 330021653 | EMA/CO |
| 330011868 | 330005602 | 1.64 | 69.3 | Palliative (P) | 2017-09-09 | 2017-09-10 | Mitotane 3 - 3.5g | 01 | N | 330021660 | BORTEZOMIB |
| 330011869 | 330009060 | 1.77 | 40 | Curative (C) | 2016-12-26 | 2017-02-19 | VINCRISTINE | N | N | 330021690 | CVP |
| 330011870 | 330009061 | 1.68 | 126 | Curative (C) | null | 2016-01-28 | EP/EMA | N | N | 330021695 | CAPECITABINE + STREPTOZOCIN |